Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.
|Articles|July 23, 2010
ONCOLOGY Current Issue: August 2010 Vol 24 No 9
The journal ONCOLOGY: Perspectives on Best Practices is a peer-reviewed open access reviews journal that focuses on practical treatment issues. Reviews are accompanied by insightful commentaries from oncologists working in a variety of settings.
Advertisement
The journal ONCOLOGY: Perspectives on Best Practices is a peer-reviewed open access reviews journal that focuses on practical treatment issues. Reviews are accompanied by insightful commentaries from oncologists working in a variety of settings.
CURRENT ISSUE
July 2013 | Volume 27 • Number 7
Advertisement
Related to this article
“Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon).
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical Oncology Congress 2026.
The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC.
The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC
3
FDA Accepts NDA for UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC
4
Sequencing CAR T-Cell Therapy and Bispecifics to Preserve T-Cell Fitness
5